查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1596655

特種非專利市場：按類型、應用和最終用途 - 2025-2030 年全球預測

Specialty Generics Market by Type (Injectables, Oral Drugs), Application (Hepatitis C, Inflammatory Conditions, Multiple Sclerosis), End-Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，特種非專利市場價值為848.6億美元，預計到2024年將達到935.6億美元，複合年成長率為10.73%，到2030年將達到1732.5億美元。

特種非專利市場包括多種特種藥物的學名藥。與傳統學名藥不同，這些藥物涉及複雜的製造流程、專有配方和分銷管道，並針對癌症、自體免疫疾病和中樞神經神經病變等利基治療領域。對特種非專利的需求源於其在保持治療效果的同時顯著降低醫療成本的潛力，這對於慢性和危及生命的疾病的管理尤其重要。應用範圍廣泛，主要關注學名藥競爭有限的治療方法。最終用途包括需要經濟有效的治療方案的醫院、診所和專業藥局。

主要市場統計
基準年[2023] 848.6億美元
預測年份 [2024] 935.6億美元
預測年份 [2030] 1732.5億美元
複合年成長率（%） 10.73%

影響該市場的主要成長要素包括慢性病盛行率上升、藥品價格上漲以及對具有成本效益的替代療法的需求不斷增加。重磅藥物的專利到期也為特種非專利製造商創造了利潤豐厚的機會。藥物輸送系統和製劑技術的技術創新也支持市場擴張。但也存在著監管嚴格、市場開拓和製造流程高成本挑戰。來自品牌專科藥物的競爭也很激烈，使新參與企業的市場進入更加複雜。

為了利用新的商機，公司應該專注於生物相似藥。生物相似藥正在迅速獲得接受，並成為政策辯論中具有影響力的推動者。對奈米製劑和長效注射劑等創新給藥方法的先進研究和開發的投資可以提供競爭優勢。擴大分銷和行銷方面的策略夥伴關係將加強市場滲透。了解區域市場動態，特別是新興經濟體的市場動態，將有助於開拓服務不足但潛力巨大的地區。然而，市場仍然受到高度監管，不斷變化的有關智慧財產權和定價策略的法律法規需要靈活的反應和策略規劃。因此，持續監控監管狀況和競爭對手的行為至關重要。在競爭激烈且開拓的專業市場中，創新和策略遠見至關重要。

市場動態：揭示快速發展的特種非專利市場的關鍵市場洞察

供需的動態交互作用正在改變特種非專利市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 擴大特殊學名藥在複雜慢性病治療的應用
    • 是否有新產品核准的監理支援政策
    • 藥物研發的重大投資
  • 市場限制因素
    • 與特種非專利相關的高成本
  • 市場機會
    • 先進醫療企業的出現和研發項目的快速增加
    • 患者人數眾多，對廉價醫療設施的需求不斷成長
  • 市場挑戰
    • 對開發和銷售成本的擔憂

波特的五力：駕馭特種非專利市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解專業非專利市場的外部影響

外部宏觀環境因素在塑造特種非專利市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解專業非專利市場的競爭狀況

對特種非專利市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣專業非專利市場供應商的績效評估

FPNV 定位矩陣是評估特種非專利市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議 規劃特種非專利市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，特種非專利市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告提供了涵蓋關鍵重點領域的市場全面分析：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 擴大採用專業學名藥來治療複雜的慢性病
      • 是否有新產品核准的支持性監理政策
      • 藥物研發的大量投資
    • 抑制因素
      • 與特種非專利相關的高成本
    • 機會
      • 存在先進的醫學公司和快速增加的研發項目
      • 患者數量不斷增加，對負擔得起的醫療設施的需求不斷增加
    • 任務
      • 對開發和行銷成本的擔憂
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 專業非專利市場：依類型

  • 注射
  • 口腔醫學

第7章 專業非專利市場：依應用分類

  • C型肝炎
  • 發炎疾病
  • 多發性硬化症
  • 腫瘤學

第8章 特種非專利市場：依最終用途

  • 醫院藥房
  • 零售藥房
  • 專業藥房

第9章 美洲的特殊非專利市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章 亞太地區特殊非專利市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲的特殊非專利市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Akorn Operating Company LLC
  • Apotex Inc.
  • Aspen Group
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc.
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Endo International plc
  • Fresenius Kabi AG
  • Generic Specialties, Inc.
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Mallinckrodt Pharmaceuticals
  • Novartis AG
  • Pfizer Inc.
  • STADA Arzneimittel AG
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Group
Product Code: MRR-205091A88B67

The Specialty Generics Market was valued at USD 84.86 billion in 2023, expected to reach USD 93.56 billion in 2024, and is projected to grow at a CAGR of 10.73%, to USD 173.25 billion by 2030.

The Specialty Generics market encompasses a range of generic versions of specialty pharmaceuticals. Unlike traditional generics, these drugs involve complex manufacturing processes, unique formulations, and distribution channels, serving niche therapeutic areas such as oncology, autoimmune diseases, and central nervous system disorders. The necessity of specialty generics stems from their potential to drastically reduce healthcare costs while maintaining treatment efficacy, which is particularly crucial in managing chronic or life-threatening conditions. Applications span multiple uses, primarily focusing on therapies with limited generic competition. End-use extends to hospitals, clinics, and specialty pharmacies that require cost-effective treatment options.

KEY MARKET STATISTICS
Base Year [2023] USD 84.86 billion
Estimated Year [2024] USD 93.56 billion
Forecast Year [2030] USD 173.25 billion
CAGR (%) 10.73%

Key growth factors influencing this market include the rising incidence of chronic diseases, escalating drug prices, and increasing demand for cost-efficient treatment alternatives. In addition, patent expirations of blockbuster drugs present lucrative opportunities for specialty generics manufacturers. Technological innovations in drug-delivery systems and formulation techniques also bolster market expansion. However, the market encounters challenges such as stringent regulatory scrutiny and the high cost of development and manufacturing processes. There is significant competition from branded specialty drugs, further complicating market entry for new players.

To capitalize on emerging opportunities, companies should focus on biosimilars, which are rapidly gaining acceptance and gaining influential traction in policy discussions. Investing in advanced R&D for innovative delivery methods, such as nano-formulations and long-acting injectables, can provide competitive advantages. Expanding strategic partnerships for distribution and marketing would enhance market penetration. Understanding regional market dynamics, especially in emerging economies, will aid in exploiting under-served yet high-potential areas. However, the market remains tightly regulated, and evolving legislation regarding intellectual property and pricing strategies demands agile responses and strategic planning. Thus, continuous monitoring of regulatory landscapes and competitor actions is imperative. The specialties' market landscape is competitive yet ripe with untapped potential, requiring innovation and strategic foresight for successful navigation.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Specialty Generics Market

The Specialty Generics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing adoption of specialty generic medicines for the treatment of complex chronic diseases
    • Presence of supportive regulatory policies regarding the approval of new products
    • Significant investments for drug development
  • Market Restraints
    • High costs associated with specialty generics
  • Market Opportunities
    • Availability of medically advanced companies and proliferating research & development programs
    • High patient population and growing demand for affordable healthcare facilities
  • Market Challenges
    • Concerns regarding development and marketing costs

Porter's Five Forces: A Strategic Tool for Navigating the Specialty Generics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Specialty Generics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Specialty Generics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Specialty Generics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Specialty Generics Market

A detailed market share analysis in the Specialty Generics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Specialty Generics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Specialty Generics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Specialty Generics Market

A strategic analysis of the Specialty Generics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Specialty Generics Market, highlighting leading vendors and their innovative profiles. These include Akorn Operating Company LLC, Apotex Inc., Aspen Group, Aurobindo Pharma Limited, Bausch Health Companies Inc., Cipla Limited, Dr. Reddy's Laboratories Ltd., Endo International plc, Fresenius Kabi AG, Generic Specialties, Inc., Hikma Pharmaceuticals PLC, Lupin Limited, Mallinckrodt Pharmaceuticals, Novartis AG, Pfizer Inc., STADA Arzneimittel AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Group.

Market Segmentation & Coverage

This research report categorizes the Specialty Generics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Injectables and Oral Drugs.
  • Based on Application, market is studied across Hepatitis C, Inflammatory Conditions, Multiple Sclerosis, and Oncology.
  • Based on End-Use, market is studied across Hospital Pharmacy, Retail Pharmacy, and Specialty Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing adoption of specialty generic medicines for the treatment of complex chronic diseases
      • 5.1.1.2. Presence of supportive regulatory policies regarding the approval of new products
      • 5.1.1.3. Significant investments for drug development
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with specialty generics
    • 5.1.3. Opportunities
      • 5.1.3.1. Availability of medically advanced companies and proliferating research & development programs
      • 5.1.3.2. High patient population and growing demand for affordable healthcare facilities
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns regarding development and marketing costs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Specialty Generics Market, by Type

  • 6.1. Introduction
  • 6.2. Injectables
  • 6.3. Oral Drugs

7. Specialty Generics Market, by Application

  • 7.1. Introduction
  • 7.2. Hepatitis C
  • 7.3. Inflammatory Conditions
  • 7.4. Multiple Sclerosis
  • 7.5. Oncology

8. Specialty Generics Market, by End-Use

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Retail Pharmacy
  • 8.4. Specialty Pharmacy

9. Americas Specialty Generics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Specialty Generics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Specialty Generics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Akorn Operating Company LLC
  • 2. Apotex Inc.
  • 3. Aspen Group
  • 4. Aurobindo Pharma Limited
  • 5. Bausch Health Companies Inc.
  • 6. Cipla Limited
  • 7. Dr. Reddy's Laboratories Ltd.
  • 8. Endo International plc
  • 9. Fresenius Kabi AG
  • 10. Generic Specialties, Inc.
  • 11. Hikma Pharmaceuticals PLC
  • 12. Lupin Limited
  • 13. Mallinckrodt Pharmaceuticals
  • 14. Novartis AG
  • 15. Pfizer Inc.
  • 16. STADA Arzneimittel AG
  • 17. Sun Pharmaceutical Industries Ltd.
  • 18. Teva Pharmaceutical Industries Ltd.
  • 19. Viatris Inc.
  • 20. Zydus Group

LIST OF FIGURES

  • FIGURE 1. SPECIALTY GENERICS MARKET RESEARCH PROCESS
  • FIGURE 2. SPECIALTY GENERICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL SPECIALTY GENERICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. SPECIALTY GENERICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. SPECIALTY GENERICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SPECIALTY GENERICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SPECIALTY GENERICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. SPECIALTY GENERICS MARKET DYNAMICS
  • TABLE 7. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY ORAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY HEPATITIS C, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY INFLAMMATORY CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 146. SPECIALTY GENERICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. SPECIALTY GENERICS MARKET, FPNV POSITIONING MATRIX, 2023